Using Preprints in NIH Grant Applications: Strategy, Timing, and Risk
NIH policy now allows preprints as citable preliminary data, and in fast-moving research areas most competitive applicants are already using them. The question is how to do it without handing reviewers a reason to doubt your application.
Table of Contents
How Preprints Changed NIH Grant Writing
NIH first signaled that preprints could be cited in grant applications in 2017, and at the time most applicants treated the guidance as a footnote. The landscape looks different now. BioRxiv and medRxiv host millions of manuscripts, and their upload pace in many areas of biomedical research rivals the peer-reviewed literature on a week-to-week basis. Reviewers who work in competitive subfields routinely cite preprints in their own applications and encounter them in the applications they review.
The shift matters because it changes the time horizon on preliminary data. Before preprints were accepted, the gap between an experiment completing and evidence of it appearing in a grant application was often twelve to eighteen months, which is roughly how long it takes to write, submit, revise, and publish in a peer-reviewed journal. A well-timed preprint can collapse that gap to weeks. For researchers in fast-moving areas like single-cell genomics, AI-assisted drug discovery, or neuroimmunology, that gap has increasingly decided whether an application looks current or dated by the time reviewers see it.
None of this means preprints are a clean substitute for peer-reviewed publications. Reviewers know the difference, and study section culture still leans toward published findings as the higher-trust signal. But used with some care, a preprint at the right moment does something a published paper can't always do: it shows that you are ahead of the field right now, not six months ago.
What NIH Policy Actually Says
NIH's official guidance allows preprints posted on recognized servers to be included in grant applications. The accepted servers include bioRxiv, medRxiv, and other platforms recognized through the NIH Preprint Pilot. Preprints can be cited as preliminary data in the Research Strategy, listed in the reference section, and included in the biosketch under publications and other research products where appropriate.
One important constraint: the application page limits still apply to your text regardless of whether a finding comes from a preprint or a journal article. Citing a preprint does not give you additional space. What it gives you is timing flexibility. You can submit an application while the journal version is still under review and list the preprint as the accessible version of the data, which lets reviewers verify it without waiting for the published paper.
NIH guidance on preprints has evolved since 2017 and will likely continue to change. Verify the current policy directly through grants.nih.gov or with your program officer before you rely on a preprint citation to a server you haven't already confirmed is on the current approved list. Guidance details sometimes shift between notice publications, and finding out at submission that a citation doesn't meet current requirements is a problem with no easy fix on a deadline.
When a Preprint Strengthens Your Application
A preprint strengthens your application most clearly when the timing is right and the data are solid. If you completed a key experiment three months before your submission deadline and the journal review cycle would have meant the paper wouldn't appear until well after your application was filed, posting to bioRxiv and citing it is almost always the better call. Reviewers can click through to the preprint, see your methods, examine the figures, and assess your data with far more confidence than they can from a compressed summary in the Approach section.
Preprints also serve a practical function at the transition from a K award to your first R01. Reviewers evaluating an R01 from a recently independent investigator want evidence that you can operate scientifically on your own, and a preprint as first or senior author from the period after your postdoc is a direct signal that you can. If the manuscript is under review, noting that in the Approach section, saying it's under review at a named journal with the preprint available at bioRxiv, shows the work is real and in the pipeline without overstating your productivity.
In fields where preprint culture is strongest, such as computational biology, structural biology, and AI-driven method development, citing a recent preprint also signals community standing. Reviewers in these areas routinely follow bioRxiv; they may already know your work before they open your application. That kind of prior recognition is hard to manufacture, and it's easy to lose by being slow to post when the rest of your field is moving fast.
When a Preprint Can Hurt You
Reviewers are not required to treat a preprint the same as a published paper, and many don't. The concerns they raise fall into a few recognizable patterns.
A preprint that has been sitting on bioRxiv for eighteen months without appearing in a peer-reviewed journal raises a question the reviewer will not always ask you directly: why hasn't it published? The charitable interpretation is a slow review process or a journal change after a rejection. The less charitable one is that reviewers elsewhere found problems with the data or methods. If you cite an aging preprint as central preliminary evidence, address its status somewhere in the Approach. Even a brief note acknowledging that it's under revision and what has changed is better than silence, which reviewers tend to fill with their own explanations.
Reviewers also consider whether preprint data underpinning a central aim has been independently replicated. A novel finding that exists only in a preprint from your own lab is weaker preliminary data than the same finding published with an independent validation. This doesn't mean you can't use it, but think carefully about how much of the application's scientific case rests on a single preprint-only result and what other data in the application partially corroborate it.
Finally, there is the reviewer who distrusts preprints on principle. This reviewer is more common in clinical and translational review panels than in basic science ones. If your target study section skews heavily toward clinical researchers, consider whether your preliminary data section can lead with peer-reviewed findings and use the preprint as supporting evidence rather than the primary citation. Check the assigned reviewer rosters from past study section meetings via NIH Reporter to get a read on the panel's general orientation before you finalize how you present unpublished work.
How to Frame Preprint Data in the Approach Section
The practical question most applicants have is how to write the citation and where to put the discussion in the application. In the reference section, the format follows standard bibliographic convention with the addition of the preprint server name and DOI. A citation like "Zhao M, et al. (2025) Title of work. bioRxiv. https://doi.org/10.1101/..." is recognized and follows the pattern reviewers and grants management staff expect.
In the Approach section, you reference preprint data the same way you reference published findings, in the flow of describing your preliminary evidence. What you don't want to do is drop a parenthetical preprint citation without explaining the data behind it. If the finding is worth citing, give it a sentence or two of context: what you did, what you found, and why it speaks directly to your proposed work. Reproducing a key figure from the preprint in the application with a clear caption crediting the preprint often serves the reviewer better than text alone, since it lets them compare what you describe against what actually appears on the server.
One detail applicants occasionally miss: if the preprint was published in a peer-reviewed journal after your submission date but before the review meeting, you may be able to update reviewer awareness through Just-in-Time materials or in response to reviewer queries about unpublished findings. This is not a standard path and depends on the circumstances, so check with your grants management specialist if the timing is close. It has been used to update the record when a paper was accepted between submission and review.
Managing the Scooping Risk
The hardest strategic question around preprints is timing. If you post to bioRxiv before you submit your grant, you make your results visible to competitors who could read them and adapt their own applications. Your assigned reviewers can't scoop you, since the review process is confidential and reviewers are bound by conflict-of-interest rules. But a competitor who reads your preprint on bioRxiv the same week you submit can incorporate your finding into their own pending or planned application.
There is no clean answer here. In very fast-moving areas, posting the preprint before submission is often the right call: the risk of being scooped exists whether or not you post, and the preprint establishes your priority date in a way that a confidential grant submission does not. In areas moving more slowly, or when the finding is particularly novel and you have a significant head start on the next step, holding the preprint until after the review meeting or until the paper is accepted is a reasonable choice.
The one mistake worth consistently warning against is posting a preprint to establish visibility without also making a real effort to get the paper into active peer review. The grant application cycle is short; the bioRxiv record is permanent. If you post to signal priority and then let the manuscript sit without active journal submission, you carry the competitive visibility of a preprint without gaining the credibility of peer review. In a compressed funding environment, that trade-off is rarely worth it.
Preprints in a Compressed Funding Portfolio
NIH funded roughly 58,000 research projects in fiscal year 2026 according to recent reporting, down from around 63,700 in the years before the portfolio reductions that began in FY2025. That compression means applications near the funding threshold face more scrutiny, and in that range, every productivity signal carries more weight than it did a few years ago.
A well-timed preprint from the months before your submission, one showing your lab is generating novel findings, is not going to rescue an application with fundamental scientific weaknesses. But it can strengthen a borderline application, one scored in the range where funding decisions turn on program priorities as much as on peer review rank. Program officers advising the funding decision see the same productivity signals the reviewers noted, and a strong preprint speaks directly to whether your lab is positioned to deliver what the application proposes.
If you don't have a preprint ready when you're planning your submission timeline, that is worth a direct conversation with your mentor and potentially your program officer before you lock in a deadline. Not every submission cycle is the right one. An application submitted six months later with stronger preliminary data, whether preprint or published, is usually a better use of your time than an application submitted on schedule with a gap in the scientific narrative that reviewers will notice and flag.
Frequently Asked Questions
Can I cite a preprint that is not on bioRxiv or medRxiv?
NIH recognizes preprints on servers listed through the NIH Preprint Pilot and related policy guidance. The list has expanded beyond bioRxiv and medRxiv, but it is not unlimited. Check the current approved server list at grants.nih.gov before citing a preprint on a less common server, and confirm with your program officer if you are uncertain. An improperly cited data source is worse than no citation at all.
Do preprints count the same as publications in the biosketch?
NIH guidance allows preprints to be listed in the biosketch under publications and other research products, but reviewers do not treat them equivalently to peer-reviewed articles when assessing the Investigator score. List them clearly as preprints so reviewers know exactly what they are. Presenting a preprint as a published paper — even accidentally through ambiguous formatting — is a factual error that damages credibility if a reviewer notices.
Should I mention a preprint to my program officer before submitting?
You don't need to, but if the preprint addresses something central to your application and the program officer might want context, mentioning it briefly in an outreach conversation is fine. Program officers are interested in your productivity and whether your science is timely. A strong recent preprint is worth a brief mention in that conversation, not a detailed summary.
What if my preprint is still unpublished when I receive the summary statement?
If reviewers flag the unpublished status as a concern in the summary statement, address it directly in your resubmission introduction. Explain the current status of the manuscript, whether it's in revision, under review at a new journal, or accepted pending proofs. Reviewers who flagged it once will look for an update. If the paper has since published, cite the published version in the resubmission and note when it appeared.
Understand Your Competitive Landscape
Knowing what is already funded in your research area helps you frame your preprint data more precisely in the innovation and significance sections. These tools let you check current funding patterns before you write.
Related Reading
Explore more resources to enhance your NIH funding knowledge
NIH R01 Preliminary Data Strategy: What Reviewers Actually Need to See
How much preliminary data is enough, what format reviewers expect, and how to frame early-stage findings to support an R01 application.
Writing the NIH R01 Approach Section
How to organize the Approach section, balance detail with space constraints, and write for a reviewer who may not share your exact expertise.
NIH Significance and Innovation: Writing the Two Sections That Open the Review
How to write Significance and Innovation sections that reviewers remember at the scoring meeting and how the two sections work together.
Writing NIH Rigor and Reproducibility: What Reviewers Check and What Gets Flagged
A practical guide to the four rigor components NIH reviewers are instructed to assess and how to address them across your application.
Trust & Transparency
How this content is reviewed before it goes live
NIH Grant Explorer combines public NIH records with editorial interpretation. We publish the review structure, methodology, and correction pathways so readers can judge the value of a guide or chart for themselves.
When a topic turns into an official policy question, we point readers back to NIH rather than pretending an independent site can replace the underlying federal guidance.
Contributors & Review Desks
See how data, strategy, and career-focused pages are reviewed.
Editorial Guidelines
How we source, update, and correct articles and tool explanations.
Data & Methodology
Refresh cadence, public-source coverage, and chart caveats.
Corrections & Contact
Send corrections, feedback, or contributor inquiries.